Ipsen launches new syringe for rare disease blockbuster

Ipsen will be launching a new pre-filled syringe for its blockbuster rare disease drug Somatuline (lanreotide) in the EU. The new design was based on several studies, involving patients, their caregivers, nurses and other healthcare professionals that aimed to inform and test enhancements to the existing pre-filled syringe. The findings from the human factor studies are being shown as a poster presentation at ENETS 2019, taking place in Barcelona this week. New features included modified ergonomics and handling, a needle shield removal system, an injection process with plunger support and heightened ease of use. The automatic, built-in safety system, which helps to prevent needle stick injury by locking in place following the administration, has not been changed. Somatuline is used for the long-term treatment of acromegaly, a rare disease caused by excess growth hormone production as a result of a tumor in the pituitary gland, in patients who cannot be treated with surgery or radiation. Some 69,000 patients worldwide are affected by this disease.